Australian company Oncology One has appointed Professor Shelley Dolan as a non-executive director.
Professor Dolan is experienced in delivering excellence in quality and performance, developing strategy, large capital schemes and innovative research projects which all require engagement with a broad range of stakeholders including patients, regulators, consultants and other personnel, commissioners, charities, and academic partners.
Oncology One chair Mary Harney, said, “The Board welcomes Professor Dolan, whose appointment brings to Oncology One a wealth of global oncology partnership experience. Professor Dolan has extensive expertise in navigating not only the patient-centric requirements of developing innovative cancer treatments, but essential commercial pathways to ensure this process is supported and successful. We feel very fortunate to welcome her to our leadership team.”
Prior to joining the Peter MacCallum Cancer Centre, Professor Dolan’s experience included senior roles in the UK. Professor Dolan has experience of joint ventures and partnership development across systems including the design and leadership of the Cancer Vanguard new care model of the NHS and well-developed risk management and corporate governance skills.
“Every day I meet people with cancer who need our care and I am looking forward to working with Oncology One to pursue more treatment options now and in the years to come," said Professor Dolan.
"Cancer affects one in two people in their lifetime and it is so important that we harness fundamental science and drug discovery translation into real-world treatments that give people better and longer lives.”
The appointment of Professor Dolan is the second new board appointment this year, with Tim Murphy joining the Oncology One Board in May 2021.
Oncology One is implementing a strategy focused on building a diversified small molecule oncology pipeline and aims to help translate more of Australia’s world-class cancer research into treatments.